News and Media

Latest News Release
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

Top feature box IMAGE ONLY - COMPANY NEWS

Company News

eMed and Cardinal Health collaborate to distribute At-Home COVID-19 Rapid Tests to thousands of pharmacies nationwide
03/09/2021
Cardinal Health to distribute eMed-virtually guided and verified tests to pharmacies in the continental United States, Puerto Rico and U.S. Virgin Islands

MIAMI — March 8, 2021 — eMed™, a digital health company democratizing healthcare through digital point-of-care solutions, and Cardinal Health (NYSE: CAH), a healthcare distributor, global manufacturer and solutions provider, today announced a collaboration to distribute millions of at-home COVID-19 rapid tests to pharmacies across the continental United States, Puerto Rico and U.S. Virgin Islands.

“There is a significant need for affordable, easily accessible coronavirus testing in this country now and in the future,” said Dr. Patrice Harris, eMed CEO. “This collaboration with Cardinal Health puts us closer to consumers, providing them with pick-up options at convenient pharmacy locations they frequent, know and trust.”

eMed offers a unique digital health platform to virtually guide individuals through the testing process by an eMed Certified Guide. The tests require no additional equipment, are authenticated and deliver results within minutes.

Under the agreement with Cardinal Health, the eMed tests will be distributed to pharmacies nationwide and be available for consumer pickup. Users will complete a questionnaire form at eMed.com, then present the completed form at a participating pharmacy to be evaluated by a pharmacist. Following their consultation with a pharmacist, they receive a test for at-home administration if eligible.

The testing process is virtually guided remotely by an eMed Certified Guide who will authenticate the test and result, automatically reporting to public health departments for tracking and tracing, thus benefitting broader public health.

“This collaboration will enable all pharmacies nationwide to offer convenient, at-home tests to their patients, and help protect against the further spread of COVID-19 in their communities,” said Victor Crawford, Pharmaceutical Segment CEO for Cardinal Health. “We are pleased to work together with eMed and use our preeminent distribution network to ensure these tests can be easily accessed by all pharmacies in the continental United States, Puerto Rico and U.S. Virgin Islands to fight the pandemic.”

Between the collaboration with Cardinal Health, individual sales, and partnerships with state governments, businesses and organizations, eMed plans to distribute and administer millions of tests throughout the country.

About eMed
eMed (www.eMed.com) is a digital health company democratizing healthcare with a digital point-of-care platform that provides fast, easy and affordable at-home health care testing, supervised and guided online by eMed Certified Guides. We embrace quantitative medicine to deliver prescribed tests and treatments directly to patients, driving better and more cost-effective health outcomes.

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 40 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

For product inquiries or to learn more, email us: BinaxNOW-Inquiries@cardinalhealth.com

  • This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA;
  • This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens; and,
  • This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.

Contacts
Media: Victor Scott, victor.scott01@cardinalhealth.com and (614) 783-2408
Investors: Kevin Moran, kevin.moran@cardinalhealth.com and (614) 757-7942

More Company News
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

04/07/2021

By Victor Crawford, Chief Executive Officer of the Pharmaceutical segment at Cardinal Health

04/07/2021

Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve...

03/30/2021

Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will...

View all company news »

* Required Fields